Lupin planning to launch around 30 generic products in US market

25 Jun 2018 Evaluate

Lupin is planning to launch around 30 generic products in the US market this year. The company has currently 162 abbreviated new drug applications pending approval with the US Food and Drug Administration (USFDA).

The company is banking on introduction of complex generics and biosimilars in the US, besides continuing focus on exclusive and semi-exclusive products in oral and injectable space to maintain its top five position in the market.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2160.85 -17.35 (-0.80%)
20-Jan-2026 10:10 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1663.60
Dr. Reddys Lab 1165.00
Cipla 1381.95
Zydus Lifesciences 879.20
Lupin 2160.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×